1 completed, 1 not yet recruiting, 1 recruiting, 1 unknown. 2 Phase 2, 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Peripheral T-Cell Lymphoma Refractory: new trials by email Literature Review of Peripheral T-Cell Lymphoma Refractory trials Research Report on Peripheral T-Cell Lymphoma Refractory
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma Zilovertamab vedotin Intravenous (IV) Infusion - 1.75 mg/kg, Lenalidomide - Peripheral T-Cell Lymphoma Refractory | Phase 2 | Not yet recruiting | Olivia Newton-John Cancer Research Institute | 25 | 2027-01-01 | 2026-11-03 |
| An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma. Azacitidine (AZA) - Peripheral T-Cell Lymphoma Refractory | Early Phase 1 | Recruiting | Second Affiliated Hospital of Soochow University | 30 | 2026-06-01 | 2026-05-20 |
| Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma LB1901 - T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory | Phase 1 | Unknown | Legend Biotech USA Inc | 50 | 2021-09-13 | 2023-10-03 |
| Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Tislelizumab - Peripheral T Cell Lymphoma, PTCL | Phase 2 | Completed | BeiGene | 77 | 2018-04-13 | 2024-10-26 |
Lymphoma, T-Cell (2) · Recurrence (2) · Immunoblastic Lymphadenopathy (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1)
Disease Attributes (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Lymphadenopathy (1)
Azacitidine (1) · Lenalidomide (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · spartalizumab (1) · tislelizumab (1)
BeiGene (1) · Legend Biotech USA Inc (1) · Olivia Newton-John Cancer Research Institute (1) · Second Affiliated Hospital of Soochow University (1)
China (2) · Australia (1) · Canada (1) · France (1) · Italy (1) · Taiwan (1) · United States (1)
Bingzong Li, Professor (1) · Eliza A Hawkes, MBBS DMedSc (1)
2017 (1)